YOUR FORESIGHT. HIS FUTURE.

The first NOAC with
a reversal agent

YOUR FORESIGHT.
HIS FUTURE.

Thông tin khoa học

Video presentation by Hugh Calkins - Safety and Efficacy of Uninterrupted Anticoagulation with Dabigatran Etexilate versus Warfarin in Patients Undergoing Catheter Ablation of Atrial Fibrillation : The Circuit Study

07:13

Video presentation by Hugh Calkins
Safety and Efficacy of Uninterrupted Anticoagulation with Dabigatran Etexilate versus Warfarin in Patients Undergoing Catheter Ablation of Atrial Fibrillation : The Circuit Study

Presentation slide: RE-DUAL PCI –antithrombotic therapy in AF patients who have undergone stent PCI

Presentation slide: RE-DUAL PCI –antithrombotic therapy in AF patients who have undergone stent PCI

NEJM Quick Take video summary of The Recircuit Trial

NEJM Quick Take video summary of The Recircuit Trial
Dabigatran was associated with fewer bleeding complications compared to uninterrupted warfarin

Are all NOACs equally safe in the Real World?

Are all NOACs equally safe in the Real World?

The US FDA Medicare study on the use of Dabigatran and Rivaroxaban in elderly patients with NVAF

The US FDA Medicare study on the use of Dabigatran and Rivaroxaban in elderly patients with NVAF

Re-ly asia Analysis and real-world evidences from Asia

Re-ly asia Analysis and real-world evidences from Asia

RE-LY low dose slides

RE-LY low dose slides

Nielsen RWE slide

Nielsen RWE slide

Uninterrupted anticoagulation in catheter ablation: insights from RE‐CIRCUIT Clinical Paper

Uninterrupted anticoagulation in catheter ablation: insights from RE‐CIRCUIT Clinical Paper

RE-DUAL PCI trial video – Commentary by Dr. Hohnloser

04:53

RE-DUAL PCI trial video – Commentary by Dr. Hohnloser

RE-DUAL PCI trial video – Presentation by Dr. Cannon

11:37

RE-DUAL PCI trial video – Presentation by Dr. Cannon

RE-DUAL PCI trial article

RE-DUAL PCI trial article

Video Summary of the RE-CIRCUIT Trial

02:14

Video Summary of the RE-CIRCUIT Trial

Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation

Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation

PC-VN-100395
Production date: Dec 2018